Detalhe da pesquisa
1.
Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
Biol Blood Marrow Transplant
; 25(3): 459-465, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30481597
2.
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
Clin Lymphoma Myeloma Leuk
; 23(7): 535-544.e1, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37127471
3.
Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myeloma.
EJHaem
; 1(1): 113-121, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35847733
4.
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.
Exp Hematol Oncol
; 7: 3, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29445583
5.
Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Cancer Med
; 10(20): 6933-6936, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34494717